Sigma-Aldrich Licenses Global Rights to Kyoto iPS Cell Patents | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that it has licensed worldwide rights to Kyoto University's induced pluripotent stem cell patent portfolio.

Under terms of the deal, iPS Academia Japan, which managed the patents and technology arising from Shinya Yamanaka's research at Kyoto University, will receive a license fee from Sigma-Aldrich. Financial and other terms of the license were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.